ClinicalTrials.gg
RecruitingNCT07675174Updated Nov 6, 2026

PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

A Phase 1/2 interventional study of Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD in GVHD - Graft-Versus-Host Disease, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Northwell Health · Phase 1/2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 6, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Graft vs Host Disease with a site in United States — 49 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Planned enrollment
62nd of 389
72 · median 30
Started
2026
with 12 others
Phase 1/2
55 of 454
5 open now
Primary completion
2030-07
later than 60 of 66 live
Registered
449th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 62nd largest by planned enrollment of the 389 interventional ones that give a count, is one of 13 that started in 2026, is one of 55 in phase 1/2, reaches primary completion later than 60 of the 66 other live ones, and was the 449th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

49 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

43 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.

Read the detailed description

The phase I portion of the clinical trial, which will define the MTD of sitagliptin, bortezomib, and PTCy as GvHD prophylaxis after reduced-intensity allogeneic PBSC transplantation. Dose escalation will follow a traditional 3+3 design. We will first test the drugs at full doses and sequentially de-escalate the doses of sitagliptin, and then bortezomib, in successive cohorts if a DLT is observed using a 3+3 design.

The phase II portion is an open-label, single-arm, Simon two-stage minimax phase II trial design.

Patients will receive RIC with fludarabine, busulfan (rATG in unrelated donor grafts) in preparation for allogeneic hematopoietic PBSC transplant from a 5/6 or 6/6 sibling donor or 7/8 or 8/8 matched unrelated donor. Patients will receive GvHD prophylaxis with sitagliptin, bortezomib, and high-dose PTCy.

03

Conditions studied

  • GVHD - Graft-Versus-Host Disease

Browse trials for

Keywords

  • GvHD
  • Allogeneic Transplant
  • Post transplant cyclophosphamide
  • Sitagliptin
  • Bortezomib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with any of the following hematologic :

    1. AML in first remission (CR1) if they have intermediate- or high-risk cytogenetic and/or molecular features, or patients in second or subsequent complete remission (CR2, CR3, etc.). Complete remission is defined as presence of \<5% blasts in the bone marrow with no morphological evidence of leukemia. Patients in CR with incomplete count recovery may be included.
    2. ALL with any of the following in CR1 or subsequent complete remission (CR2, CR3, etc.). Complete remission is defined as presence of \<5% blasts in the bone marrow with no morphological evidence of leukemia. Patients in CR with incomplete count recovery may be included.
    3. MDS with a revised International Prognostic System Score (IPSS-R) of greater than 3 at diagnosis. Patients must have \<10% blasts in the bone marrow documented within 30 days of transplant.*
    4. Therapy-related myelodysplastic disorder (t-MDS). Patients must have \<10% blasts in the bone marrow documented within 30 days of transplant.*
    5. CMML type 1 or 2. Patients must have \<10% blasts in the bone marrow documented within 30 days of transplant.* *Patients with MDS, t-MDS, and CMML will be included only in the phase I portion of the study.
  2. Patient age ≥ 18 years
  3. ≥70%
  4. Patients must also be suitable to receive an RIC regimen at the discretion of the treating physician. While there are not universally accepted or validated cut-off criteria of age, performance status, or HCT-CI for suitability for RIC, RIC transplants should be considered for patients 60 years and older and for patients \<60 years who are "less fit" (e.g., KPS \<90% and/or HCT-CI ≥3 due to lower non-relapse mortality associated with RIC).
  5. Patients receiving allogeneic PBSC grafts from HLA-matched (5/6 and 6/6 matches) siblings or matched unrelated donors (7/8 or 8/8 matches at HLA-A, B, C, DRB1 by high resolution typing) are included. All grafts will be unmanipulated (i.e., no T cell depleted or CD34 selected grafts). In addition, donors should meet institutional criteria for donation of PBSC, as well as the screening and eligibility criteria of the (NMDP) for unrelated donors, and the requirements of the United States Food and Drug Administration for HCT/P (21 CFR Part 1271).
  6. Required baseline laboratory values within 16 days prior to admission:

    1. Estimated >60 mL/min/1.72 m2
    2. Serum total ≤2 x value (except for Gilbert's disease)
    3. and ALT ≤3 x upper limit of normal value
    4. ALP ≤250 IU/l
  7. Required baseline values within 60 days prior to admission:

    1. >40%
    2. Adjusted carbon monoxide diffusing capacity (DLCO) >50%
  8. No evidence of infection (patients with immune dysfunction are at a significantly higher risk of infection from intensive therapies)
  9. Non-pregnant and non-nursing
  10. Signed written (patient must be capable of understanding the nature, potential risks and benefits of the study, and able to provide valid informed consent)
  11. Patients must otherwise fulfill institutional criteria for eligibility to undergo reduced-intensity stem cell transplantation

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice effective methods of from start of conditioning through a minimum of 90 days after the last dose of study drug. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been (stopped menstrual periods) for more than 24 consecutive months.
  2. Male subjects who refuse to practice effective barrier contraception from the start of conditioning through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post- vasectomy).
  3. Inability to provide .
  4. Patient had myocardial infarction within 6 months prior to enrollment or has Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at screening must be documented by the investigator as not medically relevant.
  5. Patients with active central nervous system leukemia
  6. Prior HSCT or an autologous HSCT in past 12 months
  7. Patients with diabetes mellitus requiring insulin secretagogues and/or insulin at time of enrollment
  8. Patients with a history of pancreatitis
  9. Patients with symptomatic cholelithiasis
  10. Known to any of the components of the treatment regimen
  11. Serious medical or psychiatric illness likely to interfere with participation in this clinical study
  12. Diagnosed or treated for another within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy
  13. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial, and throughout the duration of this trial
  14. Prisoners
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Dose Level -2

    Dosing for MTD: PTCy 50 mg/kg (day +3, +4), bortezomib 1 mg/m2 (day 0, +3), sitagliptin 400 mg (every 12 hours. day -1 to day +14)

    Drug: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

  • Experimental
    Dose Level -1

    Dosing for MTD: PTCy 50 mg/kg (day +3, +4), bortezomib 1.3 mg/m2 (day 0, +3), sitagliptin 400 mg (every 12 hours. day -1 to day +14)

    Drug: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

  • Experimental
    Dose Level 1

    Dosing for MTD: PTCy 50 mg/kg (day +3, +4), bortezomib 1.3 mg/m2 (day 0, +3), sitagliptin 600 mg (every 12 hours. day -1 to day +14)

    Drug: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

Interventions

  • DrugPost transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD

    Interventional, non-randomized, open-label, phase I/II study. Phase I: 3+3 phase dose de-escalation; phase II: Simon two-stage minimax.

06

What researchers measure

Primary outcomes

  1. Phase I - Dose Limiting Toxicity

    GvHD prophylaxis with a set dose of Post Transplant Cyclophosphamide and Bortezomib will be given in the post-transplant setting. The Sitagliptin dosing will be escalated in a 3+3 design to determine maximum tolerated dose. The dose established in phase I will be adopted for the phase II portion.

    Time frame: Day +30 post transplant determination

  2. Phase II - acute GvHD post-transplant in evaluable participants

    The phase II portion will evaluate the incidence of grades II-IV acute GvHD post-transplant through day +100. This incidence will be compared against historical controls.

    Time frame: Day 100 after allogeneic hematopoietic stem cell transplantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2030, 46 months after the start.

Of 39 phase 1/2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 76. This study's planned 46 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 30, 2026
StartActual
Aug 14, 2026was Jul 2026
Primary completionEst.
Jul 1, 2030
CompletionEst.
Jul 1, 2032
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
Northwell Health is now Recruiting
Nov 6, 2026
Start date
Jul 1, 2026→Aug 14, 2026 (actual)
Nov 6, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPhase I - Dose Limiting ToxicityTime frame: 6 months → Day +30 post transplant determination
  • ChangedBefore Phase IINow Phase II - acute GvHD post-transplant in evaluable participantsTime frame: 48 months → Day 100 after allogeneic hematopoietic stem cell transplantation
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Northwell Health · New Hyde Park, United StatesContact added k•••@northwell.edu · •••8973
Nov 6, 2026
Title
Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    Northwell Health is now Recruiting
    Start date Jul 1, 2026→Aug 14, 2026 (now actual)
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPhase I - Dose Limiting ToxicityTime frame: 6 months → Day +30 post transplant determination
    • ChangedBefore Phase IINow Phase II - acute GvHD post-transplant in evaluable participantsTime frame: 48 months → Day 100 after allogeneic hematopoietic stem cell transplantation
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Northwell Health · New Hyde Park, United StatesContact added k•••@northwell.edu · •••8973
    Title Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07675174
Lead sponsor
Northwell Health
Responsible party
Ahmad Samer Al-Homsi (System Chief, Transplant and Cellular Therapy, Northwell Health) — Principal investigator
First posted
Jun 30, 2026
Start date
Aug 14, 2026
Primary completion
Jul 1, 2030 (estimated)
Completion
Jul 1, 2032 (estimated)
Last update
Nov 6, 2026

Study contacts

Kelli Cole, MSN, FNP-BC
Contact
kcole5@northwell.edu
15167348973

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion